Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Amanda Pereira-Salgado,Angelyn Anton,Fanny Franchini,Robert K Mahar,Edmond M Kwan,Shirley Wong,Julia Shapiro,Andrew Weickhardt,Arun A Azad,Lavinia Spain,Ashray Gunjur,Javier Torres,Phillip Parente,Francis Parnis,Jeffrey Goh,Christopher Steer, Stephen Brown,Peter Gibbs,Ben Tran,Maarten IJzerman

Expert review of pharmacoeconomics & outcomes research（2023）

引用 0|浏览21

暂无评分

摘要

ICERs show ARTA had improved clinical benefit compared to DOC but at higher cost. There were no significant cost differences between combined sequences.

查看译文

关键词

Health economics,metastatic castration-resistant prostate cancer,prostate cancer,time-to-treatment failure,treatment costs,treatment sequences

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要